Clene Inc.

NASDAQ:CLNN

Biotechnology

Healthcare
$3.66 +1.35%

+$0.08 today

Market cap
$52.70M
Beta
0.92
P/E (TTM)
-2.1
EPS (TTM)
-$2.88
52W Low $3.25High $13.50

Volume 0.12M

Average 0.50M

CLNN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Clene Inc.NASDAQ: CLNN

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 11.64M shares rose 32.0% year over year, behind the +43.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 18.1% from the prior quarter. Over 3 fiscal years it compounded at +44.6% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +32.0% toward the trailing-twelve-month pace of +43.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
11.64M+18.1% QoQ
Last fiscal yearDec 2025
9.86M+41.8% YoY
LTMMar 2026
10.33M+43.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.0%——
1 year+41.8%——
3-year CAGR+44.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
9.86M USD
Year-over-year change
+41.8%
4-year CAGR
+33.8%

Weighted Avg Shares (Diluted) vs competitors

How CLNN compares with its peers on the latest reported figures

  • CLNN's LTM Mar 2026 weighted avg shares (diluted) of 10.33M shares is the lowest of the 11 companies compared; the peer median is 66.22M shares.
  • Its year-over-year change of +43.6% is the 3rd highest of 11, against a peer median of +4.2%.
  • Over three fiscal years its annual growth of +44.6% compares with a peer median of +12.1%.
CLNN Competitors Peer median
Weighted Avg Shares (Diluted) for CLNN and competitors
Company Period LTM YoY 3-year CAGR
CNTXContext Therapeutics Inc.LTM Mar 202694.36M +30.6%+81.3%
STTKShattuck Labs, Inc.LTM Mar 202684.8M +66.7%+18.0%
OVIDOvid Therapeutics Inc.LTM Mar 202674.41M +4.7%+1.5%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 202671.52M +0.4%+10.8%
WHWKWhitehawk Therapeutics IncLTM Mar 202669.18M +155.7%+40.1%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
PLRXPliant Therapeutics, Inc.LTM Mar 202661.49M +1.3%+13.5%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
ORMPOramed Pharmaceuticals Inc.LTM Mar 202642.44M +3.8%+2.8%
COYACoya Therapeutics, Inc.LTM Mar 202616.73M +5.9%+18.9%
CLNNClene Inc.LTM Mar 202610.33M +43.6%+44.6%
Peer median (excluding CLNN) 66.22M+4.2%+12.1%

Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue723K473K654K342K200K
Cost of Revenue289K26K121K70K43K
Gross Profit434K447K533K272K157K
Gross Margin60.0%94.5%81.5%79.5%78.5%
Research & Development28.42M31.92M26.66M20.06M14.01M
Selling, General & Admin18.81M16.16M14.42M13.31M9.23M
Operating Expenses50.41M48.86M41.07M33.37M23.24M
Depreciation & Amortization955K1.02M1.71M1.65M1.5M
EBITDA(8.34M)(25.6M)(43.24M)(33.69M)(22M)
EBITDA Margin-1153.9%-5412.9%-6611.8%-9851.2%-10998.0%
Operating Income(49.98M)(48.41M)(40.54M)(33.09M)(23.08M)
Operating Margin-6912.6%-10234.5%-6198.8%-9676.3%-11541.5%
Interest Income001.39M865K223K
Interest Expense870K3.3M4.56M4.06M2.68M
Other Income / Expenses39.81M18.49M(8.96M)(6.31M)(3.09M)
Income Before Tax(10.17M)(29.92M)(49.5M)(39.4M)(26.17M)
Pre-Tax Margin-1406.4%-6325.2%-7569.4%-11520.5%-13086.5%
Income Tax Expense(428K)0000
Net Income(9.74M)(29.92M)(49.5M)(39.4M)(26.17M)
Net Margin-1347.2%-6325.2%-7569.4%-11520.5%-13086.5%
EPS (Basic)(3.16)(4.69)(9.43)(5.67)(2.65)
EPS (Diluted)(3.16)(4.69)(9.43)(5.67)(2.65)
Weighted Avg Shares3.08M3.26M5.25M6.95M9.86M
Weighted Avg Shares (Diluted)3.08M3.26M5.25M6.95M9.86M

Clene Inc.

NASDAQ:CLNN

Intrinsic Alpha fair value

Locked

Current Price

$3.66

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.